Concept of Combinatorial De Novo Design of Drug‐like Molecules by Particle Swarm Optimization

We present a fast stochastic optimization algorithm for fragment‐based molecular de novo design (COLIBREE®, Combinatorial Library Breeding). The search strategy is based on a discrete version of particle swarm optimization. Molecules are represented by a scaffold, which remains constant during optimization, and variable linkers and side chains. Different linkers represent virtual chemical reactions. Side‐chain building blocks were obtained from pseudo‐retrosynthetic dissection of large compound databases. Here, ligand‐based design was performed using chemically advanced template search (CATS) topological pharmacophore similarity to reference ligands as fitness function. A weighting scheme was included for particle swarm optimization‐based molecular design, which permits the use of many reference ligands and allows for positive and negative design to be performed simultaneously. In a case study, the approach was applied to the de novo design of potential peroxisome proliferator‐activated receptor subtype‐selective agonists. The results demonstrate the ability of the technique to cope with large combinatorial chemistry spaces and its applicability to focused library design. The technique was able to perform exploitation of a known scheme and at the same time explorative search for novel ligands within the framework of a given molecular core structure. It thereby represents a practical solution for compound screening in the early hit and lead finding phase of a drug discovery project.

[1]  G. Schneider,et al.  Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. , 2007, Journal of medicinal chemistry.

[2]  G. Schneider,et al.  Protein Folding Simulation by Particle Swarm Optimization , 2007 .

[3]  Hans Matter,et al.  Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. , 2006, Journal of medicinal chemistry.

[4]  Gisbert Schneider,et al.  SMILIB: Rapid Assembly of Combinatorial Libraries in SMILES Notation , 2003 .

[5]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[6]  Alex Alves Freitas,et al.  A new discrete particle swarm algorithm applied to attribute selection in a bioinformatics data set , 2006, GECCO.

[7]  Walter Cedeño,et al.  Using particle swarms for the development of QSAR models based on K-nearest neighbor and kernel regression , 2003, J. Comput. Aided Mol. Des..

[8]  Petra Schneider,et al.  Scaffold-Hopping: How Far Can You Jump , 2006 .

[9]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[10]  Petra Schneider,et al.  Comparison of correlation vector methods for ligand-based similarity searching , 2003, J. Comput. Aided Mol. Des..

[11]  Gisbert Schneider,et al.  Flux (2): Comparison of Molecular Mutation and Crossover Operators for Ligand-Based de Novo Design , 2007, J. Chem. Inf. Model..

[12]  Li-Yeh Chuang,et al.  Improved binary PSO for feature selection using gene expression data , 2008, Comput. Biol. Chem..

[13]  Riccardo Poli,et al.  Particle swarm optimization , 1995, Swarm Intelligence.

[14]  Russell C. Eberhart,et al.  A discrete binary version of the particle swarm algorithm , 1997, 1997 IEEE International Conference on Systems, Man, and Cybernetics. Computational Cybernetics and Simulation.

[15]  G. Etgen,et al.  PPAR ligands for metabolic disorders. , 2003, Current topics in medicinal chemistry.

[16]  Gisbert Schneider,et al.  Scaffold‐Hopping: How Far Can You Jump? , 2006 .

[17]  Millard H. Lambert,et al.  Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .

[18]  Valerie J. Gillet,et al.  SPROUT: A program for structure generation , 1993, J. Comput. Aided Mol. Des..

[19]  Amedeo Caflisch,et al.  Fragment-Based de Novo Ligand Design by Multiobjective Evolutionary Optimization , 2008, J. Chem. Inf. Model..

[20]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[21]  T. Willson,et al.  Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. , 2000, Molecular cell.

[22]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[23]  D. Agrafiotis,et al.  Feature selection for structure-activity correlation using binary particle swarms. , 2002, Journal of medicinal chemistry.

[24]  Bernard Pirard,et al.  Peroxisome Proliferator-Activated Receptors target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis , 2003, J. Comput. Aided Mol. Des..

[25]  Matthias Rarey,et al.  FlexNovo: Structure‐Based Searching in Large Fragment Spaces , 2006, ChemMedChem.

[26]  Petra Schneider,et al.  De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks , 2000, J. Comput. Aided Mol. Des..

[27]  Kirsch,et al.  Virtual Screening for Bioactive Molecules by Evolutionary De Novo Design Special thanks to Neil R. Taylor for his help in preparation of the manuscript. , 2000, Angewandte Chemie.

[28]  Gisbert Schneider,et al.  Molecular design . Concepts and applications , 2009 .

[29]  T. Klabunde,et al.  GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.

[30]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[31]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[32]  Philip M. Dean,et al.  A validation study on the practical use of automated de novo design , 2002, J. Comput. Aided Mol. Des..

[33]  M. Lambert,et al.  Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. , 2007, Journal of medicinal chemistry.

[34]  Gisbert Schneider,et al.  Collection of bioactive reference compounds for focused library design , 2003 .

[35]  Peter J. B. Hancock,et al.  An Empirical Comparison of Selection Methods in Evolutionary Algorithms , 1994, Evolutionary Computing, AISB Workshop.

[36]  Yue Shi,et al.  A modified particle swarm optimizer , 1998, 1998 IEEE International Conference on Evolutionary Computation Proceedings. IEEE World Congress on Computational Intelligence (Cat. No.98TH8360).

[37]  L. Moore,et al.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.